Literature DB >> 23421999

Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.

Changyou Li1, Daniel E Johnson.   

Abstract

Human papilloma virus (HPV) infection represents an emerging risk factor in head and neck squamous cell carcinoma (HNSCC). In contrast to HPV-negative HNSCC, most cases of HPV-positive HNSCC encode wild-type p53, although the p53 protein in these cells is rapidly degraded via HPV E6-mediated ubiquitination and subsequent proteasomal degradation. This unique feature of HPV-positive HNSCC has raised hope that liberation of wild-type p53 from the E6 protein may have therapeutic benefit in this disease. Indeed, suppression of E6 expression promotes apoptosis in HPV-positive HNSCC cell lines. However, the role of p53 in mediating this cell death has not been determined. Here, we demonstrate that siRNAs targeting the E6/E7 RNA, or treatment with the proteasome inhibitor bortezomib, resulted in upregulation of functional p53 and p53 gene targets in three HPV-positive HNSCC cell lines, but not in HPV-negative HNSCC cells. Apoptosis induced by E6/E7 siRNA in HPV-positive cells was found to be dependent on p53, while bortezomib-induced cell death was modestly p53-dependent. Treatment with subtoxic doses of bortezomib led to cell cycle arrest in HPV-positive, but not HPV-negative HNSCC cells. Moreover, this cell cycle arrest was mediated by p53 and the cell cycle inhibitor p21, the product of a p53 target gene. Collectively, these findings establish that wild-type p53 encoded by HPV-positive HNSCC cells, once liberated from HPV E6, can play important roles in promoting apoptosis and cell cycle arrest.

Entities:  

Keywords:  E6; E7; HPV16; apoptosis; bortezomib; cell cycle arrest; head and neck squamous cell carcinoma; p21; p53

Mesh:

Substances:

Year:  2013        PMID: 23421999      PMCID: PMC3637351          DOI: 10.4161/cc.23882

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  66 in total

1.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.

Authors:  E Oda; R Ohki; H Murasawa; J Nemoto; T Shibue; T Yamashita; T Tokino; T Taniguchi; N Tanaka
Journal:  Science       Date:  2000-05-12       Impact factor: 47.728

2.  Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription.

Authors:  Jerry E Chipuk; Ulrich Maurer; Douglas R Green; Martin Schuler
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

3.  Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.

Authors:  Chung-Hsiang Yuan; Maria Filippova; Sandy S Tungteakkhun; Penelope J Duerksen-Hughes; John L Krstenansky
Journal:  Bioorg Med Chem Lett       Date:  2012-01-10       Impact factor: 2.823

4.  Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.

Authors:  Caroline H Shiboski; Brian L Schmidt; Richard C K Jordan
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

5.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

Authors:  Lisa Licitra; Federica Perrone; Paolo Bossi; Simona Suardi; Luigi Mariani; Raffaella Artusi; Maria Oggionni; Chiara Rossini; Giulio Cantù; Massimo Squadrelli; Pasquale Quattrone; Laura D Locati; Cristiana Bergamini; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

Review 6.  Human papillomaviruses and associated malignancies.

Authors:  R M Alani; K Münger
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice.

Authors:  Sean Jabbar; Katerina Strati; Myeong Kyun Shin; Henry C Pitot; Paul F Lambert
Journal:  Virology       Date:  2010-08-24       Impact factor: 3.616

8.  RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.

Authors:  Ni Sima; Wei Wang; Debo Kong; Dongrui Deng; Qian Xu; Jianfeng Zhou; Gang Xu; Li Meng; Yunping Lu; Shixuan Wang; Ding Ma
Journal:  Apoptosis       Date:  2008-02       Impact factor: 4.677

9.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.

Authors:  Dohun Pyeon; Michael A Newton; Paul F Lambert; Johan A den Boon; Srikumar Sengupta; Carmen J Marsit; Craig D Woodworth; Joseph P Connor; Thomas H Haugen; Elaine M Smith; Karl T Kelsey; Lubomir P Turek; Paul Ahlquist
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

10.  siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells.

Authors:  Karin Butz; Tutik Ristriani; Arnd Hengstermann; Claudia Denk; Martin Scheffner; Felix Hoppe-Seyler
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

View more
  20 in total

1.  Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis.

Authors:  Frank Ziemann; Andrea Arenz; Stefanie Preising; Claus Wittekindt; Jens P Klussmann; Rita Engenhart-Cabillic; Andrea Wittig
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Pathways enrichment analysis for differentially expressed genes in squamous lung cancer.

Authors:  Liqiang Qian; Qingquan Luo; Xiaojing Zhao; Jia Huang
Journal:  Pathol Oncol Res       Date:  2013-10-10       Impact factor: 3.201

3.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

4.  Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth.

Authors:  Changyou Li; Ann Marie Egloff; Malabika Sen; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Oncol       Date:  2014-04-18       Impact factor: 6.603

5.  Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.

Authors:  Victor Y Yazbeck; Changyou Li; Jennifer R Grandis; Yan Zang; Daniel E Johnson
Journal:  Oral Oncol       Date:  2013-11-08       Impact factor: 5.337

6.  Can liberating p53 from E6 free patients from HPV-related head and neck tumors?

Authors:  Alain C Jung
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

Review 7.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

8.  Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.

Authors:  Emiro Caicedo-Granados; Rui Lin; Caitlin Fujisawa; Bevan Yueh; Veena Sangwan; Ashok Saluja
Journal:  Oral Oncol       Date:  2014-10-11       Impact factor: 5.337

9.  TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.

Authors:  L Wang; P Zhang; D P Molkentine; C Chen; J M Molkentine; H Piao; U Raju; J Zhang; D R Valdecanas; R C Tailor; H D Thames; T A Buchholz; J Chen; L Ma; K A Mason; K-K Ang; R E Meyn; H D Skinner
Journal:  Oncogene       Date:  2016-07-18       Impact factor: 9.867

10.  Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.

Authors:  Yan Zang; Christopher J Kirk; Daniel E Johnson
Journal:  Cancer Biol Ther       Date:  2014-06-10       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.